Incidental anal 18fluorodeoxyglucose uptake: Should we further examine the patient?

Table 1 Characteristics of the global population (n = 134)

Variables	Global population	Patients non investigated	Patients investigated	P value
	n (%) or mean ± SD	n (%) or mean ± SD	n (%) or mean ± SD
	n = 134	n = 86	n = 48
Age (yr)	61.3 (12.8)	61.0 (12.1)	61.9 (14.1)	0.69
Gender (male)	84 (62.7)	56 (65.1)	28 (58.3)	0.43
18FDG PET/CT indications				0.42
Diagnosis	20 (14.9)	10 (11.6)	10 (20.8)
Follow-up of a known cancer	47 (35.1)	32 (37.2)	15 (31.3)
Staging of a known cancer	45 (33.6)	32 (37.2)	13 (27.1)
Suspicion of cancer recurrence	17 (12.7)	9 (10.5)	8 (16.7)
Diagnosis of infectious/inflammatory disease	5 (3.7)	3 (3.5)	2 (4.2)
Primitive cancer				0.13
Hematological cancer	22 (16.4)	17 (20.0)	5 (10.5)
Head and neck cancer	14 (10.4)	9 (10.5)	5 (10.4)
Lung cancer	25 (18.6)	21 (24.4)	4 (8.3)
Gynecological cancer	22 (16.4)	13 (15.1)	9 (18.8)
Urological cancer	4 (3.0)	1 (1.1)	3 (6.3)
Digestive cancer	14 (10.5)	8 (3.5)	6 (12.5)
Melanoma	9 (6.7)	5 (5.8)	4 (8.3)
Others1	7 (5.2)	3 (3.5)	4 (8.3)
Past history of pelvic radiotherapy2	13 (9.7)	8 (9.3)	5 (10.4)	0.83
Past history of proctologic diseaseb	21 (15.7)	6 (7.0)	15 (31.3)	0.0002
18FDG PET/CT
SUV mean	5.5 (2.3)	5.3 (2.1)	5.9 (2.6)	0.15
SUV max	9.6 (3.9)	9.2 (3.5)	10.2 (4.5)	0.13
MV50 (cm3)	4.1 (2.8)	4.2 (3.0)	4.0 (2.3)	0.65
MV41 (cm3)	6.6 (4.2)	6.7 (4.6)	6.4 (3.5)	0.64
MV 30 (cm3)	11.9 (7.1)	12.2 (7.7)	11.4 (5.9)	0.51

^bP < 0.01.

¹Others: sarcoma, neuroendocrine carcinoma, neurological cancer, carcinoma unknown primary syndrome.

²> 3 mo before fluorodeoxyglucose positron emission tomography with computed tomography.

¹⁸F-FDG PET/CT: Fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography; SUV: Maximum standardized uptake value; MV: Metabolic volume.